Premium
Cathepsin B‐Specific Metabolic Precursor for In Vivo Tumor‐Specific Fluorescence Imaging
Author(s) -
Shim Man Kyu,
Yoon Hong Yeol,
Ryu Ju Hee,
Koo Heebeom,
Lee Sangmin,
Park Jae Hyung,
Kim JongHo,
Lee Seulki,
Pomper Martin G.,
Kwon Ick Chan,
Kim Kwangmeyung
Publication year - 2016
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.201608504
Subject(s) - bioorthogonal chemistry , click chemistry , chemistry , azide , glycan , biochemistry , ex vivo , in vivo , conjugated system , cathepsin b , combinatorial chemistry , biology , in vitro , enzyme , microbiology and biotechnology , organic chemistry , glycoprotein , polymer
Recently, metabolic glycoengineering with bioorthogonal click reactions has focused on improving the tumor targeting efficiency of nanoparticles as delivery vehicles for anticancer drugs or imaging agents. It is the key technique for developing tumor‐specific metabolic precursors that can generate unnatural glycans on the tumor‐cell surface. A cathepsin B‐specific cleavable substrate (KGRR) conjugated with triacetylated N ‐azidoacetyl‐ d ‐mannosamine (RR‐S‐Ac 3 ManNAz) was developed to enable tumor cells to generate unnatural glycans that contain azide groups. The generation of azide groups on the tumor cell surface was exogenously and specifically controlled by the amount of RR‐S‐Ac 3 ManNAz that was fed to target tumor cells. Moreover, unnatural glycans on the tumor cell surface were conjugated with near infrared fluorescence (NIRF) dye‐labeled molecules by a bioorthogonal click reaction in cell cultures and in tumor‐bearing mice. Therefore, our RR‐S‐Ac 3 ManNAz is promising for research in tumor‐specific imaging or drug delivery.